Loading…
Mirum Pharmaceuticals, Inc. is projected to rise to $122.21 by 2027, a +26% move from its current price of $97.33. MIRM is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $94.61 | $97.37 | $100.21 | +0.04% |
| May 30 | $93.53 | $97.41 | $101.45 | +0.08% |
| May 31 | $92.72 | $97.45 | $102.42 | +0.13% |
| Jun 1 | $92.05 | $97.49 | $103.26 | +0.17% |
| Jun 2 | $91.47 | $97.53 | $104.00 | +0.21% |
| Jun 3 | $90.94 | $97.57 | $104.69 | +0.25% |
| Jun 4 | $90.47 | $97.61 | $105.32 | +0.29% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $90.47 | $97.61 | $105.32 | +0.29% |
| Week 2 | $87.92 | $97.90 | $109.01 | +0.59% |
| Week 3 | $86.08 | $98.19 | $112.00 | +0.88% |
| Week 4 | $84.59 | $98.47 | $114.64 | +1.17% |
| Week 5 | $83.33 | $98.76 | $117.05 | +1.47% |
| Week 6 | $82.23 | $99.05 | $119.32 | +1.77% |
| Week 7 | $81.24 | $99.34 | $121.46 | +2.06% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Mirum Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.
The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is approved as treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects and for adjunctive treatment of patients with peroxisomal disorders, including peroxisome biogenesis disorder-Zellweger spectrum disorder and Smith-Lemli-Opitz syndrome; and Chenodal, a tablet, which is approved for the treatment of radiolucent stones in the gallbladder, and under development for the treatment cerebrotendinous xanthomatosis. In addition, it develops Volixibat, an oral and minimally absorbed agent designed to inhibit IBAT, currently under Phase 2b clinical trial for the treatment of adult patients with cholestatic liver diseases; Brelovitug, for the treatment of chronic HDV infection, which is in Phase 2 clinical trial; and MRM-3379, that is in Phase 2 clinical study for the treatment of FXS.
The company has a collaboration agreement with the Shire International GmbH; License Agreement with Pfizer Inc.; Sanofi-Aventis Deutschland GmbH; Novartis Pharma AG; Lonza Ltd.; Enthorin Therapeutics, LLC and Dart Neuroscience LLC; Asset Purchase Agreement with Asklepion Pharmaceuticals, LLC; License and Manufacturing Agreement with LGM Pharma; and Asset Purchase Agreement with Travere Therapeutics, Inc. The company was incorporated in 2018 and is headquartered in Foster City, California.
Mirum is a Healthcare stock currently trading at $98.62 with a market capitalization of $6.01B and a market rank of 1214.
The 2026 forecast shows a low of $75.56 and a high of $139.48, with an average of $98.62.
From 2027 onward, forecasts rise to $125.99 (2027), $176.00 (2028), $223.36 (2029), and $267.99 (2030). The trajectory continues to $303.87 (2031), $321.83 (2032), $372.54 (2033), $433.46 (2034), and $534.89 (2035), then much higher at $848.16 (2040) and $1,815.97 (2050).
The longer-range outlook shows bullish sentiment with notable upside, including a 2030 average of $267.99 (ROI 171.7), a 2040 average of $848.16 (ROI 760), and a 2050 average of $1,815.97 (ROI 1741.4). These figures imply meaningful upside over the coming years, though they are estimates and not guarantees.
A major floor 17.6% below — a decisive break under it would weaken the trend.
The nearest floor, 6.0% below — buyers have tended to step in here.
The nearest ceiling, 14.4% above — a clean break opens room to run.
A major ceiling 23.3% above — clearing it would confirm fresh momentum.
Key MIRM support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of MIRM market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $98.49 | Sell | $98.57 | Sell |
| MA 10 | $100.63 | Sell | $99.74 | Sell |
| MA 20 | $101.96 | Sell | $100.05 | Sell |
| MA 50 | $96.83 | Buy | $97.91 | Sell |
| MA 100 | $95.87 | Buy | $93.40 | Buy |
| MA 200 | $83.92 | Buy | $83.96 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 46.51 | Neutral |
| Stoch RSI (14) | 11.50 | Buy |
| CCI (20) | -64.37 | Neutral |
| Williams %R (14) | -88.43 | Info |
| MACD (12,26,9) | -1.04 | Sell |
| ROC (12) | -9.17 | Sell |
| Bollinger %B (20,2) | 0.28 | Neutral |
| Stochastic %K (14) | 11.57 | Buy |
| TRIX (15) | 0.23 | Buy |
| Awesome (5,34) | -0.63 | Sell |
| Ultimate (7,14,28) | 37.07 | Neutral |
| Momentum (10) | -9.55 | Sell |
| Aroon Osc (25) | 56.00 | Buy |
| Hull MA (9) | 98.31 | Sell |
| ADX (14) | 13.88 | Neutral |
| ATR (14) | 2.55 | Info |
The 30-day technical picture is bullish for Mirum, with RSI(14) at 50 and a current bullish tilt in sentiment.
The 50-day simple moving average sits at $96.57, while the 200-day simple moving average is at $83.53, indicating a positive near-term trend relative to historical levels.
Support is lined up at $91.49 and resistance at $111.39, framing a near-term trading range. The 30-day price range spans from $80.76 to $120.42, highlighting a breadth of movement over the past month.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $75.56 | $97.33 | $136.73 | 0% | Neutral | |
| $96.43 | $122.21 | $164.36 | +26% | Bullish | |
| $127.61 | $166.42 | $232.31 | +71% | Bullish | |
| $158.20 | $211.34 | $303.83 | +117% | Bullish | |
| $184.09 | $251.25 | $370.31 | +158% | Bullish | |
| $202.93 | $282.44 | $425.43 | +190% | Bullish | |
| $212.63 | $301.39 | $462.93 | +210% | Bullish | |
| $238.38 | $343.75 | $537.45 | +253% | Bullish | |
| $269.79 | $395.45 | $628.45 | +306% | Bullish | |
| $327.96 | $488.31 | $787.88 | +402% | Bullish | |
| $472.46 | $755.56 | $1,299.04 | +676% | Bullish | |
| $895.87 | $1,621.86 | $3,058.85 | +15.7x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $75.56 | $97.33 | $114.01 | +0.00% |
| June 2026 | $82.24 | $96.70 | $116.47 | -0.65% |
| July 2026 | $85.23 | $101.10 | $123.51 | +4.56% |
| August 2026 | $86.81 | $103.69 | $128.05 | +2.56% |
| September 2026 | $85.33 | $102.51 | $127.71 | -1.14% |
| October 2026 | $86.36 | $104.30 | $130.99 | +1.75% |
| November 2026 | $89.07 | $108.07 | $136.67 | +3.62% |
| December 2026 | $88.13 | $107.40 | $136.73 | -0.62% |
Click any year to see its month-by-month MIRM forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
By 2026, MIRM could reach as high as $136.73, with a base case around $97.33 and support toward $75.56 — roughly 0% from $97.33. Price action looks broadly range-bound.
Expect MIRM to range from $96.43 to $164.36 through 2027. The $122.21 average target implies a +26% move from current prices. That is up +26% on the projected 2026 average. Buyers look set to stay in control over this stretch.
The MIRM price prediction for 2028 points to an average of $166.42 (low $127.61, high $232.31) — a potential gain of +71% on today's $97.33. Momentum favours further upside here.
In 2029, MIRM is projected to trade between $158.20 and $303.83, averaging $211.34 — a potential gain of +117% from today's $97.33. That is up +27% on the projected 2028 average. Buyers look set to stay in control over this stretch.
Mirum Pharmaceuticals, Inc.'s 2030 outlook centres on $251.25, within a $184.09 to $370.31 range. That is up +19% on the projected 2029 average. That marks a +158% change versus current levels. Momentum favours further upside here.
By 2031, MIRM could reach as high as $425.43, with a base case around $282.44 and support toward $202.93 — roughly +190% from $97.33. Buyers look set to stay in control over this stretch.
Expect MIRM to range from $212.63 to $462.93 through 2032. The $301.39 average target implies a +210% move from current prices. That is up +7% on the projected 2031 average. Momentum favours further upside here.
The MIRM price prediction for 2033 points to an average of $343.75 (low $238.38, high $537.45) — a potential gain of +253% on today's $97.33. Buyers look set to stay in control over this stretch.
In 2034, MIRM is projected to trade between $269.79 and $628.45, averaging $395.45 — a potential gain of +306% from today's $97.33. That is up +15% on the projected 2033 average. Momentum favours further upside here.
Mirum Pharmaceuticals, Inc.'s 2035 outlook centres on $488.31, within a $327.96 to $787.88 range. That is up +23% on the projected 2034 average. That marks a +402% change versus current levels. Buyers look set to stay in control over this stretch.
By 2040, MIRM could reach as high as $1,299.04, with a base case around $755.56 and support toward $472.46 — roughly +676% from $97.33. Momentum favours further upside here.
Expect MIRM to range from $895.87 to $3,058.85 through 2050. The $1,621.86 average target implies a +15.7x move from current prices. That is up +115% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in MIRM today (≈ 10.274324 MIRM) could be worth
$16,663.53
+$15,663.53 (+1566%) by 2050 · US Dollar
Based on the average projected MIRM price of $1,621.86 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in MIRMwould be worth at today's price.
$1,000 invested in MIRM on May 27, 2025 (≈ 22.794621 MIRM) would be worth
$2,218.6
+$1,218.6 (+121.9%) today · 2.22× · US Dollar
Based on a MIRM entry price of $43.87 vs. today's $97.33.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $96.95 | $1,003.92 | +0.4% |
| 1 month ago | $92.48 | $1,052.44 | +5.2% |
| 3 months ago | $92.19 | $1,055.75 | +5.6% |
| 6 months ago | $73.05 | $1,332.38 | +33.2% |
| 1 year ago | $43.87 | $2,218.6 | +121.9% |
| All time (5.0y) ago | $16.65 | $5,845.65 | +484.6% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our MIRM forecast.
Our base-case forecast reaches $190.00 around 2029.
Implied market cap at $190.00: $11.59B
The multi-year forecast sketches a sustained ascent for Mirum. In 2030, the average price is projected at $267.99 with a minimum of $194.27 and a maximum of $399.73, reflecting an implied ROI of 171.7 and a bullish outlook.
Looking further out, the 2040 forecast contends with an average of $848.16, a low of $518.85, and a high of $1,484.54, with an implied ROI of 760 and continued bullish sentiment.
By 2050, the forecast points to an average of $1,815.97, a low of $971.24, and a high of $3,497.75, supported by an implied ROI of 1741.4. These projections suggest substantial upside over the long horizon, but they remain estimates and are not guaranteed; outcomes depend on market conditions and evolving fundamental factors.
Tap a question to reveal the answer.
2030 average price: $267.99; min $194.27; max $399.73; ROIPct 171.7.
Forecast sentiment turns bullish from 2027 onward, with rising averages (e.g., 2027 $125.99, 2028 $176.00, 2029 $223.36, 2030 $267.99) and higher ROI in later years (2030 ROI 171.7; 2040 ROI 760; 2050 ROI 1741.4); 2026 is Neutral.
2040 average price: $848.16; min $518.85; max $1,484.54; ROIPct 760.
2050 average price: $1,815.97; min $971.24; max $3,497.75; ROIPct 1741.4.
Current price: $98.62; Market cap: $6.01B.
Mirum Pharmaceuticals, Inc. Community Discussion
0Share your Mirum Pharmaceuticals, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.